Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets Activity (Detail)

v3.20.4
Intangible Assets Activity (Detail) - USD ($)
Nov. 30, 2020
May 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]    
Leronlimab (PRO 140) patent $ 3,500,000 $ 3,500,000
Website development costs 20,000 20,000
Accumulated amortization (6,184,000) (5,190,000)
Total amortizable intangible assets, net 12,462,000 13,456,000
Patents currently not amortized 0 0
Carrying value of intangibles, net 12,462,000 13,456,000
ProstaGene, LLC    
Acquired Finite-Lived Intangible Assets [Line Items]    
ProstaGene, LLC intangible asset acquisition $ 15,126,000 $ 15,126,000